lung%20cancer
LUNG CANCER
Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.

Epidemiology

  • The leading cause of cancer death worldwide & the 2nd most common cancer in both men & women 
  • It was estimated that 80-90% of all lung cancer cases are due to tobacco or cigarette smoking
    • Approximately 50% of lung cancer cases are from active smokers & approximately 15% are from second-hand smoke exposure during childhood & adolescence

Definition

  • Lung cancer develops when cells inside the lungs (lining of the bronchi) begin to grow out of control, invade nearby tissues and metastasize

Signs and Symptoms

Primary Tumor-Related

  • Cough, dyspnea, hemoptysis, chest discomfort

Due to Intrathoracic Spread

  • May involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner’s syndrome), chest wall & pleura (chest pain, dyspnea), vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dysphagia)


Due to Metastatic Spread

  • Bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, skin nodules


Paraneoplastic Syndromes

  • Hypercalcemia (nausea or vomiting, abdominal pain, constipation, polyuria, thirst, dehydration, confusion, irritability)
  • Syndrome of inappropriate antidiuretic hormone (SIADH) production (confusion, seizures, decreased level of consciousness, coma)
  • Cushing’s syndrome (weakness, muscle wasting, decreased level of consciousness, confusion, psychosis, dependent edema, hypokalemic alkalosis, hyperglycemia)
  • Others (digital clubbing, hypertrophic osteoarthropathy, Lambert-Eaton myasthenic syndrome, peripheral neuropathy, cortical cerebellar degeneration)

Other Symptoms

  • Malaise, loss of appetite & weight loss

Risk Factor Assessment

Patient Factors
  • Patients ages 65 years old and above (average is 70 years old) are at a greater risk of lung cancer development
  • Smoking cigarettes increases the risk of developing lung cancer
    • Number of packs of cigarettes smoked per day & the years spent smoking is directly related to the development of lung cancer
  • Passive smokers have 24% increased risk of developing lung cancer
  • Occupational & environmental exposures
    • Asbestos, arsenic, beryllium, chloromethyl ether, chromium, nickel, polycyclic aromatic hydrocarbons, vinyl chloride, radon, cadmium, diesel exhaust fumes, coal smoke and soot, talc, uranium
  • Previous lung disease (eg chronic obstructive pulmonary disease with FEV1 ≤70% predicted, pulmonary fibrosis)
  • History of any cancer or thoracic radiation
    • Risk of cancer due to radiation is proportional to the dose received & usually starts approximately 20 years after exposure
  • Family history of lung cancer
  • Beta carotene supplements in heavy smokers
  • Exposure to infectious agents: Human immunodeficiency virus (HIV), fungal infections, tuberculosis, aspiration, infectious respiratory symptoms
  • Survivors of lung cancer, lymphomas, cancers of the head and neck or smoking-related cancers
Radiologic Factors
  • Associated with scarring or suspicion of inflammatory changes
  • Fluorodeoxyglucose (FDG) avidity (PET scan) 
  • Size, shape and density of the pulmonary nodule 
Physical Examination
  • The 2 important factors that predict the survival of patients following treatment are weight loss & performance status
  • Patients who lost <10% of their pre-treatment weight & are mobile have better chances of survival
Laboratory Tests
  • Should include electrolytes, liver function tests (LFTs), calcium, lactate dehydrogenase (LDH), blood urea nitrogen (BUN), creatinine 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 16 Oct 2019
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
Roshini Claire Anthony, 16 Oct 2019

Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.

Pearl Toh, 14 Oct 2019
About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.
Tristan Manalac, 11 Sep 2018
The immediate reduction of cigarette nicotine content results in greater improvements in levels of smoke exposure biomarkers than gradual reduction, though withdrawal symptoms are stronger, according to a recent study.